These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 5317363)

  • 1. Cryoprecipitated factor VIII concentrate.
    Pool JG
    Thromb Diath Haemorrh Suppl; 1968; 35():35-40. PubMed ID: 5317363
    [No Abstract]   [Full Text] [Related]  

  • 2. Storage of thawed cryoprecipitated AHF is better at room temperature than at 1 degree C to 6 degrees C for factor VIII content.
    Saxena S; Odono V; Francis R; Shulman IA
    Arch Pathol Lab Med; 1991 Apr; 115(4):343-5. PubMed ID: 1901483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of iodine-125-labeled factor VIII in patients with von Willebrand's disease.
    Over J; Sixma JJ; Bouma BN; Bolhuis PA; Vlooswijk RA; Beeser-Visser NH
    J Lab Clin Med; 1981 Mar; 97(3):332-44. PubMed ID: 6780640
    [No Abstract]   [Full Text] [Related]  

  • 4. [Value of cryoprecipitate in the treatment of von Willebrand's disease].
    Dyszy-Laube B; Zywicka-Lopaciuk H; Lopaciuk S
    Pediatr Pol; 1970 Aug; 45(8):911-5. PubMed ID: 5311867
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of the residual plasma following preparation of factor VIII cryoprecipitate.
    Oberman HA; Penner JA
    JAMA; 1968 Sep; 205(12):819-21. PubMed ID: 5695503
    [No Abstract]   [Full Text] [Related]  

  • 7. A new method of demonstrating the effect of therapy in von Willebrand's disease.
    Sutor AH; Bowie EJ; Owen CA
    Mayo Clin Proc; 1971 May; 46(5):345-6. PubMed ID: 5314172
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrated antihemophilic factor (AHF) from outdated blood.
    Weaver RA; Gabriel DA; Langdell RD
    Transfusion; 1967; 7(3):168-73. PubMed ID: 6025692
    [No Abstract]   [Full Text] [Related]  

  • 10. Glycine-precipitated antihemophilic factor concentrates and their clinical use.
    Wagner RH; Roberts HR; Webster WP; Shanbrom E; Brinkhous KM
    Thromb Diath Haemorrh Suppl; 1968; 35():41-8. PubMed ID: 5761073
    [No Abstract]   [Full Text] [Related]  

  • 11. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic materials used in the treatment of coagulation defects.
    Smith JK; Bidwell E
    Clin Haematol; 1979 Feb; 8(1):183-206. PubMed ID: 367662
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor VIII (antihemophilic globulin).
    Aronson DL
    Semin Thromb Hemost; 1979; 6(1):12-27. PubMed ID: 390712
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic studies in von Willebrand's disease: alteration of factor VIII/von Willebrand protein after transfusion with plasma concentrates in patients with von Willebrand's disease.
    Sultan Y; Simeon J; Maisonneuve P; Caen JP
    Thromb Haemost; 1976 Feb; 35(1):110-9. PubMed ID: 1085498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryoprecipitated factor 8 concentrate.
    Pool JG
    Bibl Haematol; 1970; 34():23-9. PubMed ID: 5436350
    [No Abstract]   [Full Text] [Related]  

  • 16. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.
    Bergamaschini L; Mannucci PM; Federici AB; Coppola R; Guzzoni S; Agostoni A
    J Lab Clin Med; 1995 Mar; 125(3):348-55. PubMed ID: 7897302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of congenital deficiencies of factor VIII and factor IX.
    Rizza CR; Biggs R
    Thromb Diath Haemorrh Suppl; 1968; 35():73-84. PubMed ID: 5317365
    [No Abstract]   [Full Text] [Related]  

  • 19. Preparation and testing of antihemophilic globulin (Factor 8) sources for transfusion therapy in hemophilia. Description of a new sterile concentrate process for blood banks.
    Pool JG
    Scand J Clin Lab Invest; 1965; 17():Suppl 84:70-7. PubMed ID: 5862567
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hemotherapy in blood coagulation disorders].
    Griffitts JJ
    Bibl Haematol; 1967; 27():294-6. PubMed ID: 5317772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.